Studies on vancomycin pharmacokinetics in acute kidney injury (AKI) patients on high-volume peritoneal dialysis (HVPD) are lacking. We studied the pharmacokinetics of intravenous (IV) vancomycin in AKI patients treated by HVPD who received a prescribed single IV dose of vancomycin (15 - 20 mg/kg total body weight) to determine the extent of vancomycin removal and to establish vancomycin dosing guidelines for the empirical treatment of AKI patients receiving HVPD. The application of 18 mg/kg vancomycin every 48 - 72 hours in AKI patients undergoing HVPD was required to maintain therapeutic concentrations.
ZarjouA., AgarwalA.Sepsis and acute kidney injury.J Am Soc Nephrol2011; 22: 999–1006.
2.
DavenportA.Dialytic treatment for septic patients with acute kidney injury.Kidney Blood Press Res2011; 34: 218–24.
3.
PonceD., BerbelM.N., Regina de GoesC., AlmeidaC.T., BalbiA.L.High-volume peritoneal dialysis in acute kidney injury: indications and limitations.Clin J Am Soc Nephrol2012; 7: 887–94.
4.
PonceD., BuffarahM.B., GoesC., BalbiA.Peritoneal dialysis in acute kidney injury: trends in the outcome across time periods.PLOS One2015; 10: e0126436.
SingerM., DeutschmanC.S., SeymourC.W., SingerM., Shankar-HariM., AnnaneD.The third international consensus definitions for sepsis and septic shock (sepsis-3).JAMA2016; 315(8): 801–10.
7.
VandecasteeleS.J., De VrieseA.S.Recent changes in vancomycin use in renal failure.Kidney Int2010; 77: 760–4.
8.
BlotS., LipmanJ., RobertsD.M., RobertsJ.A.The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?Diagn Microbiol Infect Dis2014; 79: 77–84.
9.
McKenzieC.Antibiotic dosing in critical illness.J Antimicrob Chemother2011; 66(Suppl 2): ii25–31.
10.
RybakM.J.The pharmacokinetic and pharmacodynamic properties of vancomycin.Clin Inf Dis2006; 42: S35–9.
LewisS.J., MuellerB.A.Antibiotic dosing in patients with acute kidney injury: “Enough but not too much.”J Int Care Med2016; 31(3): 164–76.
13.
ZamonerW., FreitasF.M., GarmsD.S.S., Gobo-OliveiraM., BalbiA.L., PonceD.Pharmacokinetics and pharmacodynamics of antibiotics in critically ill acute kidney injury patients.Pharma Res Per2016; 4(6): e00280.
14.
Kidney Disease:Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury.Kidney Int Suppl2012; 2: 1–138.
15.
SilvaJ.M., OliveiraA.M., CamposE.V., GomezD.S., FerreiraM.C., GiraudC.S.Vancomycin dose adjustment in severe burn patients based on trough level for drug effectiveness against pathogens at 1 mg/l minimum inhibitory concentration.Crit Care2013; 17(Suppl 3): P29.
16.
RoggeM.C., JohnsonC.A., ZimmermanS.W., WellingP.G.Vancomycin disposition during continuous ambulatory peritoneal dialysis: a pharmacokinetic analysis of peritoneal drug transport.Antimicrob Agents Chemother1985; 27: 578–82.
17.
AwdishuL., BouchardJ.How to optimize drug delivery in renal replacement therapy.Semin Dial2011; 24(2): 176–82.
18.
PetejovaN., MartinekA., ZahalkovaJ., DuricovaJ., BrozmanovaH., UrbanekK.Vancomycin removal during low-flux and high-flux extended daily hemodialysis in critically ill septic patients.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub2012; 156(4): 342–47.
19.
KielsteinJ.T., CzockD., SchöpkeT., HaferC., Bode-BögerS.M., KuseE.Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis.Crit Care Med2006; 34: 51–6.
20.
Launay-VacherV., IzzedineH., MercadalL., DerayG.Clinical review: use of vancomycin in haemodialysis patients.Crit Care2002; 6: 313–16.
